Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.86 USD | +9.83% | +1.67% | -45.15% |
04-29 | Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance | MT |
04-29 | Prime Medicine Gets FDA Clearance for PM359 IND Application | DJ |
Sales 2024 * | 14.43M 1.15B | Sales 2025 * | 14.72M 1.18B | Capitalization | 560M 44.78B |
---|---|---|---|---|---|
Net income 2024 * | -218M -17.42B | Net income 2025 * | -223M -17.82B | EV / Sales 2024 * | 31.3 x |
Net cash position 2024 * | 109M 8.73B | Net cash position 2025 * | 275M 22.01B | EV / Sales 2025 * | 19.4 x |
P/E ratio 2024 * |
-2.63
x | P/E ratio 2025 * |
-3
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.98% |
Latest transcript on Prime Medicine, Inc.
1 day | +9.83% | ||
1 week | +1.67% | ||
Current month | -30.57% | ||
1 month | -30.57% | ||
3 months | -35.11% | ||
6 months | -13.06% | ||
Current year | -45.15% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 70 | 30/06/20 | |
Allan Reine
DFI | Director of Finance/CFO | 49 | 01-16 |
Chief Operating Officer | 52 | 31/08/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 30/11/21 | |
Robert Nelsen
BRD | Director/Board Member | 60 | 31/08/20 |
Michael Kelly
BRD | Director/Board Member | 67 | 31/10/21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.71% | 2 M€ | -25.75% | ||
0.00% | 9 M€ | +6.62% | - |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 4.86 | +9.83% | 1,268,471 |
26/04/24 | 4.425 | +2.91% | 641,595 |
25/04/24 | 4.3 | -8.51% | 848,913 |
24/04/24 | 4.7 | -2.08% | 522,474 |
23/04/24 | 4.8 | +0.42% | 850,794 |
Delayed Quote Nasdaq, April 29, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.15% | 560M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.01% | 22.18B | |
-16.67% | 21.2B | |
-9.70% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- PRME Stock